Most people think of digestion as something that happens to food. Enzymes break things down, nutrients get absorbed, what’s left moves on. Clean, mechanical, linear.
The reality is messier — and far more interesting. Your gut is not a passive processing tube. It is an ecosystem of trillions of microorganisms that are constantly metabolizing, transforming, and signaling. Some of the molecules they produce do not stay in the gut. They get absorbed, travel to the liver, circulate in blood, and land on receptors in organs that have nothing obvious to do with digestion — your heart, your pancreas, your adipose tissue, and your brain.
Secondary bile acids are a prominent example of this. They are molecules your body makes, your microbiome transforms, and your biology uses as signals in ways researchers are only beginning to fully understand. They are also among the most compelling functional biomarkers of gut health that no standard panel reports.
From your liver to your microbiome — and back
The story starts in the liver, not the gut.
Your liver synthesizes primary bile acids — cholic acid and chenodeoxycholic acid — from cholesterol. These are conjugated to glycine or taurine, stored in the gallbladder, and released into the small intestine after a meal to help emulsify dietary fats for absorption. The process is efficient: roughly 95% of bile acids are reabsorbed in the terminal ileum and returned to the liver via the portal vein for reuse. This recycling loop — the enterohepatic circulation — completes six to ten times a day.¹
The remaining 5% escapes to the colon, where gut bacteria get to work. Through a series of enzymatic transformations — deconjugation, dehydroxylation, dehydrogenation, and epimerization — gut microbes convert primary bile acids into secondary bile acids.¹ The two most abundant secondary bile acids in humans are deoxycholic acid (DCA), derived from cholic acid, and lithocholic acid (LCA), derived from chenodeoxycholic acid. These transformations require specific bacterial enzymes that are not distributed evenly across the microbiome. They are the metabolic output of particular microbial communities, meaning that the secondary bile acid pool you carry is a direct fingerprint of your gut microbial composition.²
That matters because secondary bile acids are not waste. They are signaling molecules — ligands for receptors that regulate metabolism, immune function, glucose homeostasis, and energy expenditure across multiple organs.
The receptors that make bile acids a gut-body communication system
Two receptors sit at the heart of the bile acid signaling network: FXR and TGR5.
FXR — the farnesoid X receptor — is a nuclear receptor found in the liver, intestine, kidney, and adrenal gland. Primary bile acids are its main endogenous ligands. When bile acids activate FXR in the liver, it suppresses de novo bile acid synthesis and regulates cholesterol and lipid metabolism. In the intestine, FXR activation triggers release of FGF19, a hormone that travels to the liver and further suppresses bile acid production — a classical feedback loop.² The glucose connection is direct: FXR-null mice develop severe insulin resistance and impaired hepatic glucose production, establishing FXR as a regulator of glucose homeostasis well beyond its traditional lipid-handling role.³
TGR5 — a G-protein-coupled receptor expressed in the gut, liver, brown adipose tissue, and muscle — responds to secondary bile acids more potently than primary ones.⁴ In intestinal L-cells, TGR5 activation triggers secretion of glucagon-like peptide-1 (GLP-1) — the same hormone that GLP-1 receptor agonist medications target. In thermogenically active tissues, TGR5 activation increases energy expenditure by promoting thyroid hormone conversion.⁴ The implication is striking: the secondary bile acids your gut microbiome produces after a meal are directly stimulating the same TGR5/GLP-1 axis that GLP-1 receptor agonists were designed to activate pharmacologically.
This is the gut-liver crosstalk that this series has been building toward. A molecular conversation where what you eat shapes your microbiome, your microbiome shapes your bile acid profile, and your bile acid profile shapes metabolic hormone secretion, lipid handling, and glucose regulation across multiple organs simultaneously.
The upstream inputs — and why the exposome matters here
No other molecule in this series is more directly shaped by exposome inputs than secondary bile acids. Understanding what modifies the secondary bile acid pool is essentially understanding what modifies the gut microbiome — and that list is long.
Diet is the most powerful lever. Dietary fiber feeds the bile acid-metabolizing bacterial communities. Populations consuming high-fiber diets have larger, more diverse secondary bile acid pools. Red meat and high-fat Western diets increase specifically DCA production. The Mediterranean dietary pattern consistently modifies bile acid composition in a direction associated with better metabolic outcomes. The DIRECT-PLUS randomized trial revealed that your starting bile acid profile significantly modifies how much you benefit from a Mediterranean diet.⁵ Researchers found that certain bile acids act as "response biomarkers," essentially predicting whether your BMI will drop or remain stable during the intervention.
Antibiotic exposure disrupts the secondary bile acid pool profoundly and sometimes persistently. The bacterial enzymes responsible for bile acid dehydroxylation — the transformation of primary to secondary bile acids — require specific microbial taxa that can take months to recover after antibiotic use. Gut transit time matters: slower transit allows more complete microbial transformation of bile acids. Faster transit reduces secondary bile acid production. Even xenobiotic exposures — medications, environmental chemicals — alter microbiome composition and secondarily the bile acid landscape.
Genetics plays a role too: variants in FXR and TGR5 receptor genes influence how the same bile acid signal is interpreted at the tissue level. The Dongfeng-Tongji cohort study found that specific FXR receptor polymorphisms modified cardiovascular risk independently — participants carrying certain FXR variants had 121–129% higher CVD risk even before accounting for bile acid levels.⁶
What the evidence actually shows
The human outcomes data for secondary bile acids is building rapidly — and it sits in both directions.
Elevated DCA specifically has emerged as a concern in multiple independent datasets. The Dongfeng-Tongji cohort — 1,234 participants with newly diagnosed type 2 diabetes followed for a median of 5.7 years — found that, within this diabetic population, higher levels of unconjugated secondary bile acids and DCA were independently and linearly associated with incident CVD. Hazard ratios of 1.62 and 1.46 per quartile comparison, respectively, after multivariable adjustment.⁶ DCA is the same secondary bile acid consistently associated with colorectal cancer risk in prior literature — its biological profile includes promotion of cellular proliferation, DNA damage, and inflammatory signaling at colonocyte surfaces.
The bile acid pool as a whole, however, is more nuanced. Ursodeoxycholic acid (UDCA) — a secondary bile acid produced by specific gut bacteria — has well-established hepatoprotective and anti-inflammatory properties and is already used clinically for liver disease management. The signal is not “more secondary bile acids is worse”. It is “a dysregulated pool, dominated by DCA and LCA relative to UDCA and other protective species, reflects a state of gut dysbiosis, often driven by Western-style dietary patterns.”¹
The intervention data support this interpretation. Dietary patterns that enrich fiber-fermenting and bile acid-metabolizing bacterial communities (Mediterranean eating patterns, plant-rich diets, fermented foods) consistently shift the secondary bile acid pool in a more favorable direction.⁵ Probiotic and prebiotic interventions show effects on circulating bile acids, though consistency across studies is limited.⁷
The foil: what the zonulin test is actually measuring
If secondary bile acids represent a genuinely informative window into gut-liver crosstalk, the contrast with the most widely sold gut health biomarker in functional and integrative medicine is instructive.
Zonulin, marketed as a marker of intestinal permeability (the functional state behind the popular concept of “leaky gut”), has enormous commercial traction. The biological premise is legitimate: zonulin is a real protein involved in regulating tight junction permeability in the intestinal epithelium, and intestinal permeability is a genuinely relevant physiological variable.
The problem is the assay.
A 2019 study published in PLoS ONE used immunoprecipitation followed by mass spectrometric analysis to identify what commercial zonulin ELISA kits are detecting. The answer: haptoglobin and complement C3 — not zonulin.⁸ Two widely used commercial kits from different manufacturers were both detecting the wrong proteins. A 2020 commentary in Gut extended this critique directly: “zonulin as a biomarker is highly disputed,” noting that commercial ELISA measurements are not detecting human zonulin protein.⁹
The biology of leaky gut is real. The available commercial measurement does not reliably capture it. This is the labeling failure the previous series described, a functional concept with legitimate scientific grounding, attached to an assay that has not been validated to measure what it claims to measure.
What the measurement requires
Secondary bile acids, measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS) with appropriate species-level resolution, represent the opposite situation: a technically demanding measurement that captures a real biological signal, connected to mechanistically plausible and increasingly replicated human outcome data. The analytical challenge is distinguishing primary from secondary species, conjugated from unconjugated forms, and individual molecular species within each class. This requires dedicated separation methods and reference standards for each species of interest in the LC-MS/MS assay.
The Lysophosphatidylcholine (LPC) angle is worth noting here. LPC is mechanistically connected to gut-liver crosstalk through a separate but parallel pathway. Dietary phosphatidylcholine is hydrolyzed in the intestinal lumen by pancreatic phospholipase A2, releasing LPC, which is absorbed and transported to the liver.¹⁰ Hepatic phospholipid composition, including LPC uptake and recycling, directly influences the liver’s capacity to handle fat and maintain membrane integrity — with LPC-containing polyunsaturated fatty acids demonstrating hepatoprotective effects in overnutrition models.¹¹ The gut-liver conversation happens simultaneously on multiple lipid channels. Secondary bile acids are the most directly microbiome-derived signal in that conversation, but they do not travel alone.
What this can and cannot tell you
A secondary bile acid profile measured by LC-MS/MS serves as a high-resolution functional readout of your gut’s current metabolic activity. While traditional 16S or metagenomic sequencing identifies ‘who is there,’ this profile captures ‘what they are doing.’ Its primary diagnostic utility lies in identifying functional dysbiosis—specifically, a shift toward a pro-inflammatory or pro-carcinogenic bile acid pool—before traditional markers of metabolic syndrome or liver damage may appear. It provides a bridge between microbial presence and systemic metabolic interpretability.1
What it cannot tell you is which of those inputs is primarily responsible for an abnormal result, or what the optimal intervention is for a specific individual profile. The field has not yet established clinical reference ranges for secondary bile acid species in metabolically healthy populations across diverse ancestries and dietary patterns. The cardiovascular outcome data is concentrated in people with type 2 diabetes. Extrapolation to general wellness monitoring requires caution.
The open and genuinely important question: as LC-MS/MS-based bile acid profiling becomes more accessible, can compositional bile acid signatures (beyond single species) serve as actionable indicators for personalized dietary or microbiome-targeted intervention? The DIRECT-PLUS data suggest the signal is there. Building the intervention evidence on top of it is the field’s current work.
Why this matters beyond the gut
The gut microbiome conversation has been dominated for years by diversity scores and microbiome sequencing reports that tell you which bacteria are present without telling you what those bacteria are doing. Secondary bile acids are a direct functional output, a measurement of microbial activity, not microbial presence.
You cannot feel your bile acid profile. But it is shaped by every meal, every treatment with antibiotics, every shift in gut transit time, and the entire dietary history your microbiome has been working with. It is one of the clearest molecular traces the gut leaves on the rest of the body.
That trace, it turns out, reaches a lot further than the liver.
Scientific note: This article cites peer-reviewed evidence, clinical guidelines, and reported professional consensus throughout. Sources are independently verifiable and listed below. Claims about individual tests are scoped to the published literature cited and do not constitute medical advice.
José Carlos Bozelli Jr., PhD, is a lipid biochemist, omics data scientist, and scientific writer. He advises biotech, CRO, and health-tech teams on lipidomics, large-scale omics data pipelines, and biomarker science, and translates complex molecular data into decisions for scientists, clinicians, and builders.
The content of this article is for informational and educational purposes only and does not constitute medical advice. Consult a qualified healthcare professional before making decisions based on biomarker results.
References
Collins SL, et al. Bile acids and the gut microbiota: metabolic interactions and impacts on disease. Nat Rev Microbiol. 2022;20(4):236–247. DOI: 10.1038/s41579-021-00630-4
Guzior DV, Quinn RA. Review: microbial transformations of human bile acids. Microbiome. 2021;9(1):140. DOI: 10.1186/s40168-021-01101-1
Ma K, et al. Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest. 2006;116(4):1102–1109. DOI: 10.1172/JCI25604
Thomas C, et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab. 2009;10(3):167–177. DOI: 10.1016/j.cmet.2009.08.001
Gao P, et al. Gut microbial metabolism of bile acids modifies the effect of Mediterranean diet interventions on cardiometabolic risk in a randomized controlled trial. Gut Microbes. 2024;16(1):2295942. DOI: 10.1080/19490976.2023.2295942
Lu Q, et al. Gut microbiota-derived secondary bile acids, bile acids receptor polymorphisms, and risk of cardiovascular disease in individuals with newly diagnosed type 2 diabetes. Am J Clin Nutr. 2023;117(4):746–756. DOI: 10.1016/j.ajcnut.2023.01.011
Pushpass RAG, et al. Circulating bile acids as a link between the gut microbiota and cardiovascular health. Nutr Res Rev. 2022;35(2):274–289. DOI: 10.1017/S0954422421000081
Ajamian M, et al. Serum zonulin as a marker of intestinal mucosal barrier function: may not be what it seems. PLoS ONE. 2019;14(1):e0210728. DOI: 10.1371/journal.pone.0210728
Massier L, et al. Blurring the picture in leaky gut research: how shortcomings of zonulin as a biomarker mislead the field of intestinal permeability. Gut. 2021;70(10):1801–1802. DOI: 10.1136/gutjnl-2020-323026
Hui DY. Intestinal phospholipid and lysophospholipid metabolism in cardiometabolic disease. Curr Opin Lipidol. 2016;27(3):254–260. DOI: 10.1097/MOL.0000000000000290
Chin C, et al. Blood-derived lysophospholipid sustains hepatic phospholipids and fat storage necessary for hepatoprotection in overnutrition. J Clin Invest. 2023;133(10):e162192. DOI: 10.1172/JCI162192
Ahmad TR, Haeusler RA. Bile acids in glucose metabolism and insulin signalling — mechanisms and research needs. Nat Rev Endocrinol. 2019;15(12):701–712. DOI: 10.1038/s41574-019-0266-7